Table of Contents

1 Market Overview

• 1.1 Objectives of Research
  • 1.1.1 Definition
  • 1.1.2 Specifications
• 1.2 Market Segment
  • 1.2.1 by Type
    • 1.2.1.1 Inhaled Corticosteroids (ICS)
    • 1.2.1.2 Long-Acting Beta2-Agonists (LABA)
    • 1.2.1.3 Antihistamine
    • 1.2.1.4 Vasodilators
    • 1.2.1.5 Short-Acting Beta2-Agonists (SABA)
    • 1.2.1.6 Anticholinergics
    • 1.2.1.7 Combination Drugs
    • 1.2.1.8 MAbs
    • 1.2.1.9 Enzymes
    • 1.2.1.10 Antibiotics & Antileukotrienes
  • 1.2.2 by Application
    • 1.2.2.1 Asthma & COPD
    • 1.2.2.2 Allergic Rhinitis
    • 1.2.2.3 Pulmonary Arterial Hypertension
    • 1.2.2.4 Cystic Fibrosis
  • 1.2.3 by Regions

2 Industry Chain

• 2.1 Industry Chain Structure
• 2.2 Upstream
• 2.3 Market
  • 2.3.1 SWOT
  • 2.3.2 Dynamics

3 Environmental Analysis

• 3.1 Policy
• 3.2 Economic
• 3.3 Technology
• 3.4 Market Entry

4 Market Segmentation by Type

• 4.1 Market Size
  • 4.1.1 Inhaled Corticosteroids (ICS) Market, 2013-2018
  • 4.1.2 Long-Acting Beta2-Agonists (LABA) Market, 2013-2018
  • 4.1.3 Antihistamine Market, 2013-2018
  • 4.1.4 Vasodilators Market, 2013-2018
  • 4.1.5 Short-Acting Beta2-Agonists (SABA) Market, 2013-2018
  • 4.1.6 Anticholinergics Market, 2013-2018
  • 4.1.7 Combination Drugs Market, 2013-2018
  • 4.1.8 MAbs Market, 2013-2018
  • 4.1.9 Enzymes Market, 2013-2018
  • 4.1.10 Antibiotics & Antileukotrienes Market, 2013-2018
• 4.2 Market Forecast
  • 4.2.1 Inhaled Corticosteroids (ICS) Market Forecast, 2019-2024
  • 4.2.2 Long-Acting Beta2-Agonists (LABA) Market Forecast, 2019-2024
  • 4.2.3 Antihistamine Market Forecast, 2019-2024
  • 4.2.4 Vasodilators Market Forecast, 2019-2024
  • 4.2.5 Short-Acting Beta2-Agonists (SABA) Market Forecast, 2019-2024
  • 4.2.6 Anticholinergics Market Forecast, 2019-2024
  • 4.2.7 Combination Drugs Market Forecast, 2019-2024
  • 4.2.8 MAbs Market Forecast, 2019-2024
  • 4.2.9 Enzymes Market Forecast, 2019-2024
  • 4.2.10 Antibiotics & Antileukotrienes Market Forecast, 2019-2024

5 Market Segmentation by Application

• 5.1 Market Size
  • 5.1.1 Asthma & COPD Market, 2013-2018
  • 5.1.2 Allergic Rhinitis Market, 2013-2018
  • 5.1.3 Pulmonary Arterial Hypertension Market, 2013-2018
  • 5.1.4 Cystic Fibrosis Market, 2013-2018
• 5.2 Market Forecast
  • 5.2.1 Asthma & COPD Market Forecast, 2019-2024
  • 5.2.2 Allergic Rhinitis Market Forecast, 2019-2024
  • 5.2.3 Pulmonary Arterial Hypertension Market Forecast, 2019-2024
  • 5.2.4 Cystic Fibrosis Market Forecast, 2019-2024

6 Market Segmentation by Region

• 6.1 Market Size
  • 6.1.1 Asia-Pacific
    • 6.1.1.1 Asia-Pacific Market, 2012-2018
    • 6.1.1.2 Asia-Pacific Market by Type
    • 6.1.1.3 Asia-Pacific Market by Application
  • 6.1.2 North America
    • 6.1.2.1 North America Market, 2012-2018
    • 6.1.2.2 North America Market by Type
    • 6.1.2.3 North America Market by Application
  • 6.1.3 Europe
    • 6.1.3.1 Europe Market, 2012-2018
    • 6.1.3.2 Europe Market by Type
    • 6.1.3.3 Europe Market by Application
  • 6.1.4 South America
    • 6.1.4.1 South America Market, 2012-2018
    • 6.1.4.2 South America Market by Type
    • 6.1.4.3 South America Market by Application
  • 6.1.5 Middle East & Africa
    • 6.1.5.1 Middle East & Africa Market, 2012-2018
    • 6.1.5.2 Middle East & Africa Market by Type
    • 6.1.5.3 Middle East & Africa Market by Application
• 6.2 Market Forecast
  • 6.2.1 Asia-Pacific Market Forecast, 2019-2024
  • 6.2.2 North America Market Forecast, 2019-2024
  • 6.2.3 Europe Market Forecast, 2019-2024
  • 6.2.4 South America Market Forecast, 2019-2024
  • 6.2.5 Middle East & Africa Market Forecast, 2019-2024

7 Market Competitive

• 7.1 Global Market by Vendors
• 7.2 Market Concentration
• 7.3 Price & Factors
• 7.4 Marketing Channel

8 Major Vendors

• 8.1 AstraZeneca plc
• 8.2 Bayer AG
• 8.3 Teva Pharmaceutical Industries Ltd
• 8.4 Actelion Pharmaceuticals, Inc.
• 8.5 Boehringer Ingelheim GmbH
• 8.6 F. Hoffmann-La Roche Ltd.
• 8.7 Merck & Co., Inc.
• 8.8 Novartis AG
• 8.9 GlaxoSmithKline plc
• 8.10 Sunovion Pharmaceuticals

9 Conclusion

Summary
The global Pulmonary Drugs market will reach xxx Million USD in 2019 with CAGR xx% 2019-2024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.
Based on products type, the report describes major products type share of regional market. Products mentioned as follows:
Inhaled Corticosteroids (ICS)
Long-Acting Beta2-Agonists (LABA)
Antihistamine
Vasodilators
Short-Acting Beta2-Agonists (SABA)
Anticholinergics
Combination Drugs
MAbs
Enzymes
Antibiotics & Antileukotrienes
Leading vendors in the market are included based on profile, business performance etc. Vendors mentioned as follows:
AstraZeneca plc
Bayer AG
Teva Pharmaceutical Industries Ltd
Actelion Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Novartis AG
GlaxoSmithKline plc
Sunovion Pharmaceuticals
Based on Application, the report describes major application share of regional market. Application mentioned as follows:
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Based on region, the report describes major regions market by products and application. Regions mentioned as follows:
Asia-Pacific
North America
Europe
South America
Middle East & Africa